Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
Akihito Tsuji, Masato Nakamura, Takanori Watanabe, Dai Manaka, Hiroshi Matsuoka, Masato Kataoka, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Topics & Concepts
PanitumumabMedicineKRASCetuximabInternal medicineIrinotecanColorectal cancerOncologyClinical endpointResponse Evaluation Criteria in Solid TumorsChemotherapy regimenRashPhases of clinical researchChemotherapyClinical trialCancerColorectal Cancer Treatments and StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer Research